Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $8.24 Average PT from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned a consensus recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $8.24.

ZNTL has been the topic of a number of recent research reports. Guggenheim dropped their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Wedbush reissued a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. UBS Group dropped their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. HC Wainwright dropped their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. Finally, Wells Fargo & Company dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $2.43 on Wednesday. Zentalis Pharmaceuticals has a one year low of $1.61 and a one year high of $18.07. The business’s fifty day moving average price is $2.65 and its 200-day moving average price is $3.11. The stock has a market capitalization of $173.17 million, a PE ratio of -0.98 and a beta of 1.81.

Insiders Place Their Bets

In other news, Director Jan Skvarka acquired 60,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now owns 149,551 shares of the company’s stock, valued at $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Ingmar Bruns acquired 20,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the transaction, the insider now directly owns 36,629 shares in the company, valued at approximately $83,514.12. The trade was a 120.27 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently modified their holdings of ZNTL. SG Americas Securities LLC increased its position in shares of Zentalis Pharmaceuticals by 84.8% during the 3rd quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock valued at $96,000 after purchasing an additional 11,997 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in Zentalis Pharmaceuticals by 195.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 45,506 shares of the company’s stock valued at $167,000 after acquiring an additional 30,098 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Zentalis Pharmaceuticals by 44.3% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 67,893 shares of the company’s stock valued at $250,000 after acquiring an additional 20,848 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after acquiring an additional 5,333 shares during the period. Finally, Carson Advisory Inc. boosted its holdings in Zentalis Pharmaceuticals by 55.8% during the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock valued at $90,000 after acquiring an additional 8,800 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.